Nanjing Medlander Medical Technology Co.,Ltd. (SHA:688273)
China
· Delayed Price · Currency is CNY 44.29
+0.81 (1.86%)
At close: Mar 9, 2026
SHA:688273 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 431.59 | 418.41 | 320.87 | 353.18 | 338.7 | Upgrade
|
| Other Revenue | - | 6.14 | 19.96 | 23.71 | 2.94 | Upgrade
|
| Revenue | 431.59 | 424.55 | 340.82 | 376.89 | 341.64 | Upgrade
|
| Revenue Growth (YoY) | 1.66% | 24.57% | -9.57% | 10.32% | 1.52% | Upgrade
|
| Cost of Revenue | - | 119.06 | 98.92 | 118.88 | 92.66 | Upgrade
|
| Gross Profit | 431.59 | 305.49 | 241.9 | 258.01 | 248.98 | Upgrade
|
| Selling, General & Admin | - | 149.36 | 127.84 | 116.86 | 102.16 | Upgrade
|
| Research & Development | - | 57.33 | 58.24 | 41.34 | 37.23 | Upgrade
|
| Other Operating Expenses | 326.9 | -6.96 | -10.75 | -7.59 | -4.57 | Upgrade
|
| Operating Expenses | 326.9 | 200.54 | 175.78 | 153.44 | 135.38 | Upgrade
|
| Operating Income | 104.69 | 104.94 | 66.12 | 104.57 | 113.6 | Upgrade
|
| Interest Expense | - | -1.06 | -0.38 | -0.3 | -0.15 | Upgrade
|
| Interest & Investment Income | - | 13.26 | 28.76 | 17.28 | 5.55 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.03 | -0.03 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.41 | -0.57 | -0.27 | -0.09 | -0.03 | Upgrade
|
| EBT Excluding Unusual Items | 104.29 | 116.59 | 94.19 | 121.45 | 118.97 | Upgrade
|
| Impairment of Goodwill | - | -9.61 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 1.02 | 0.65 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.26 | 0.23 | -0 | 0.31 | Upgrade
|
| Asset Writedown | - | -0.18 | - | - | - | Upgrade
|
| Other Unusual Items | - | 17.57 | 6.4 | 24.44 | 10.46 | Upgrade
|
| Pretax Income | 104.29 | 125.13 | 101.48 | 145.9 | 129.73 | Upgrade
|
| Income Tax Expense | 2.23 | 16.23 | 9 | 16.61 | 10.04 | Upgrade
|
| Earnings From Continuing Operations | 102.06 | 108.9 | 92.48 | 129.29 | 119.7 | Upgrade
|
| Minority Interest in Earnings | - | -7.32 | -2.67 | -7.6 | -1.31 | Upgrade
|
| Net Income | 102.06 | 101.58 | 89.82 | 121.68 | 118.38 | Upgrade
|
| Net Income to Common | 102.06 | 101.58 | 89.82 | 121.68 | 118.38 | Upgrade
|
| Net Income Growth | 0.47% | 13.10% | -26.19% | 2.79% | -2.91% | Upgrade
|
| Shares Outstanding (Basic) | 98 | 99 | 100 | 83 | 75 | Upgrade
|
| Shares Outstanding (Diluted) | 98 | 99 | 100 | 83 | 75 | Upgrade
|
| Shares Change (YoY) | -0.73% | -1.46% | 20.00% | 11.11% | 0.00% | Upgrade
|
| EPS (Basic) | 1.04 | 1.03 | 0.90 | 1.46 | 1.58 | Upgrade
|
| EPS (Diluted) | 1.04 | 1.03 | 0.90 | 1.46 | 1.58 | Upgrade
|
| EPS Growth | 1.21% | 14.77% | -38.49% | -7.49% | -2.92% | Upgrade
|
| Free Cash Flow | - | -7.2 | 61.76 | 72.41 | 134.01 | Upgrade
|
| Free Cash Flow Per Share | - | -0.07 | 0.62 | 0.87 | 1.79 | Upgrade
|
| Dividend Per Share | - | 0.800 | 0.600 | 1.300 | - | Upgrade
|
| Dividend Growth | - | 33.33% | -53.85% | - | - | Upgrade
|
| Gross Margin | 100.00% | 71.95% | 70.97% | 68.46% | 72.88% | Upgrade
|
| Operating Margin | 24.26% | 24.72% | 19.40% | 27.74% | 33.25% | Upgrade
|
| Profit Margin | 23.65% | 23.93% | 26.35% | 32.29% | 34.65% | Upgrade
|
| Free Cash Flow Margin | - | -1.70% | 18.12% | 19.21% | 39.23% | Upgrade
|
| EBITDA | 123.22 | 123.47 | 79.37 | 115.3 | 122.62 | Upgrade
|
| EBITDA Margin | 28.55% | 29.08% | 23.29% | 30.59% | 35.89% | Upgrade
|
| D&A For EBITDA | 18.52 | 18.52 | 13.25 | 10.73 | 9.02 | Upgrade
|
| EBIT | 104.69 | 104.94 | 66.12 | 104.57 | 113.6 | Upgrade
|
| EBIT Margin | 24.26% | 24.72% | 19.40% | 27.74% | 33.25% | Upgrade
|
| Effective Tax Rate | 2.14% | 12.97% | 8.87% | 11.38% | 7.74% | Upgrade
|
| Revenue as Reported | - | 424.55 | 340.82 | 376.89 | 341.64 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.